Table 2.
Baseline characteristics of CCP patients according to age.
| CCP patients | <70 years old | 70–79 years old | ≥80 years old |
|---|---|---|---|
| N (% all) | 93 (9.97%) | 184 | 655 |
| Age (average CI 95%) | 61.39 (59.6–63.1) | 75.6 (75.2–76.02) | 87.5 (87.2–87.9) |
| Women n (% group) |
41/93 = 44.08% | 82 (44.6%) | 365 (55.7%) |
| CCP criteria number (average CI 95%) | 2.9 (2.7–3.22) | 3.69 (3.5–3.8) | 4.02 (3.94–4.12) |
| Diabetes mellitus n (% group) | 53 (57.%) | 125 (67.9%) | 16 (48.2%) |
| Hypertension n (% group) | 63 (67.7%) | 160 (87.0%) | 551 (84.1%) |
| Dyslipidemia n (% group) | 55 (59.1%) | 125 (67.9%) | 341 (52.1%) |
| Atrial fibrillation n (% group) | 17 (18.3%) | 60 (32.6%) | 248 (37.9%) |
| Ischaemic cardiopathy n (% group) | 20 (21.5%) | 43 (23.4%) | 133 (20.3%) |
| Peripheral artery disease n (% group) | 17 (18.3%) | 41 (22.3%) | 91 (13.9%) |
| Chronic kidney insufficiency < 30 mlClCr n (% group) | 12 (12.9%) | 24 (13.1%) | 80 (12.2%) |
| Heart failure n (% group) | 17/93 = 18.27% | 53 (28.8%) | 233 (35.6%) |
| Charlson score (average CI 95%) | 2.17 (1.87–2.47) | 2.7 (2.5–2.9) | 2.52 (2.42–2.63) |
| Stroke n (% group) | 21 (22.6%) | 51 (27.8%) | 185 (28.3%) |
| CHA2DS2VASC score (average CI 95%) | 4 (3.11–4.9) | 5.17 (4.84–5.51) | 5.03 (4.88–5.20) |
| Stroke risk/year (average CI 95%) | 4.78 (3.55–6.02) | 6.81 (6.2–7.4) | 6.57 (6.27–6.87) |
| Daily medications number (average CI 95%) | 9.21 (8.37–10.6) | 10.1 (9.5–10.53) | 8.5 (8.24–8.77) |
| Cognitive impairment n (% group) | 14 (15.1%) | 35 (19.0%) | 289 (44.1%) |
| Pfeiffer test score (average CI 95%) | 1.40 (0.86–1.95) | 1.53 (1.19–1.89) | 3.71 (3.46–3.97) |
| Barthel score (average CI 95%) | 82.8 (77.3–88.4) | 80.67 (76.9–84.4) | 59. (57.1–62.08) |
| Fall risk n (% group) | 5 (5.4%) | 31 (16.8%) | 152 (23.2%) |
| Antiaggregant treatment n (% group) | 30 (32.3%) | 82 (44.6%) | 273 (41.7%) |
| Anticoagulant treatment n (% group) | 25 (26.9%) | 55 (29.9%) | 175 (26.7%) |
| HAS_BLED (average CI 95%) | 2.93 (2.22–3.65) | 3.06 (2.81–3.31) | 2.96 (2.82–3.11) |
| Bleeding risk/year (average CI 95%) | 5.18 (3.0–7.37) | 4.89 (4.0–5.8) | 4.95 (4.5–5.41) |
| Statin treatment n (% group) | 54 (58.1%) | 118 (64.1%) | 251 (38.3%) |
| CNS depressant drugs n (% group) | 44 (47.3%) | 97 (52.7%) | 373 (56.9%) |
| Death n (% group) | 12 (12.9%) | 48 (26.1%) | 259 (39.5%) |
| Average follow-up time n (days CI 95%) | 1348 (719–1977) | 947 (901–993) | 971 (825–1117) |